RGABX
Price
$66.55
Change
-$0.26 (-0.39%)
Updated
Dec 19 closing price
SPECX
Price
$28.58
Change
+$0.07 (+0.25%)
Updated
Dec 19 closing price
Ad is loading...

RGABX vs SPECX

Header iconRGABX vs SPECX Comparison
Open Charts RGABX vs SPECXBanner chart's image
American Funds Growth Fund of Amer R2
Price$66.55
Change-$0.26 (-0.39%)
VolumeN/A
CapitalizationN/A
Alger Spectra A
Price$28.58
Change+$0.07 (+0.25%)
VolumeN/A
CapitalizationN/A
RGABX vs SPECX Comparison Chart
Loading...
View a ticker or compare two or three
VS
RGABX vs. SPECX commentary
Dec 20, 2024

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is RGABX is a Buy and SPECX is a StrongBuy.

FUNDAMENTALS
Fundamentals
RGABX has more cash in the bank: 277B vs. SPECX (3.71B). RGABX (0.00) and SPECX (0.00) have matching dividends . RGABX was incepted earlier than SPECX: RGABX (23 years) vs SPECX (55 years). SPECX is a more actively managed with annual turnover of: 59.63 vs. RGABX (31.00). RGABX has a lower initial minimum investment than SPECX: RGABX (250) vs SPECX (1000). SPECX annual gain was more profitable for investors over the last year : 41.49 vs. RGABX (18.59). RGABX return over 5 years is better than : 38.50 vs. SPECX (27.22).
RGABXSPECXRGABX / SPECX
Total Expense RatioN/AN/A-
Annual Report Gross Expense RatioN/AN/A-
Fund Existence23 years55 years-
Gain YTD16.57039.20942%
Front LoadN/AN/A-
Min. Initial Investment250100025%
Min. Initial Investment IRAN/AN/A-
Net Assets277B3.71B7,458%
Annual Yield % from dividends0.000.00-
Returns for 1 year18.5941.4945%
Returns for 3 years2.2322.0510%
Returns for 5 years38.5027.22141%
Returns for 10 years60.5963.3896%
View a ticker or compare two or three
Ad is loading...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
STOCK / NAMEPrice $Chg $Chg %
WIT3.710.08
+2.20%
Wipro Limited
MVBF19.960.08
+0.40%
MVB Financial Corp
EXPO90.920.20
+0.22%
Exponent
CODX0.73N/A
-0.06%
Co-Diagnostics
RCKT11.35-0.39
-3.32%
Rocket Pharmaceuticals